Your destination for today’s heart health conversation.
Despite many recent advances in cardiovascular diagnosis and treatment, misdiagnosis is still a common concern for patients at risk of heart disease, the leading cause of death in the United States. A complex web of symptoms, circumstances and comorbidities means that it’s not always easy for physicians to correctly identify conditions on the first visit.
In the last few years, we’ve seen an explosion in consumer health devices, from watches that monitor your heart rate to apps that track everything from sleep to blood pressure to calories. However, various misconceptions, anxieties and fears still keep patients from talking openly with their doctors, particularly when it comes to heart disease. Learn how technology can help not hinder the quality of healthcare you receive.
Patients are spending more and more on healthcare, but is it for the right tests and diagnostics? CMS reported that in 2017, individuals paid upwards of $10,000 on average on healthcare expenses alone, but not all were necessary. The fears surrounding high healthcare costs and unnecessary tests among Americans are a real concern. Find out what can be done in this short blog.
The American Heart Association recently reported that cardiovascular disease impacts nearly half of all American adults. What you might not know is that the risk is exponentially higher within the firefighter community. Read Dennis’ heartwarming story to learn how he discovered he had coronary artery disease and how his life was saved.
71 percent of Americans don’t know that heart disease is the leading cause of death; meanwhile, prevalence of younger individuals with heart disease is rising. Do what you can to improve your chances of living a healthy life with these five tips.
Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease offers higher diagnostic accuracy, fewer unnecessary tests and higher confidence in identifying patients needing treatment.
In the last few years, we’ve seen an explosion in consumer health devices, from watches that monitor your heart rate to apps that track everything from sleep to blood pressure to calories. However, various misconceptions, anxieties and fears still keep patients from talking openly with their doctors, particularly when it comes to heart disease. Learn how technology can help not hinder the quality of healthcare you receive.
Patients are spending more and more on healthcare, but is it for the right tests and diagnostics? CMS reported that in 2017, individuals paid upwards of $10,000 on average on healthcare expenses alone, but not all were necessary. The fears surrounding high healthcare costs and unnecessary tests among Americans are a real concern. Find out what can be done in this short blog.
The American Heart Association recently reported that cardiovascular disease impacts nearly half of all American adults. What you might not know is that the risk is exponentially higher within the firefighter community. Read Dennis’ heartwarming story to learn how he discovered he had coronary artery disease and how his life was saved.
71 percent of Americans don’t know that heart disease is the leading cause of death; meanwhile, prevalence of younger individuals with heart disease is rising. Do what you can to improve your chances of living a healthy life with these five tips.
Neither men nor women are safe from the perils of heart disease. Know the symptoms, ask the right questions and partner with your physician to better manage your heart health.
More than 100 million Americans suffer from chronic conditions, like heart disease and diabetes. Not surprisingly, 37 percent of Americans have avoided the doctor. Learn why and the risks of avoiding optimal care.
February marks Heart Health Awareness Month, and to do our part, we developed this page to provide resources for patients to help them better understand the facts about heart disease and the risks of avoiding care.
The HeartFlow Analysis has the highest accuracy compared to other non-invasive tests1 and has been proven to reduce the number of unnecessary tests and procedures.2
Learn what other tests lack and why the HeartFlow Analysis sets a new standard of care.
The patient journey to a coronary artery disease (CAD) diagnosis can be long and challenging, but it doesn’t have to be. Learn more about the pros and cons of traditional diagnostic tests and how the HeartFlow Analysis offers a more streamlined process.
We conducted a survey of more than 1,500 adults in the U.S. and uncovered misconceptions about the leading cause of death in men and women, as well as a shared positive outlook on innovations in healthcare that will help transform the diagnosis and treatment of heart disease.
Learn more in our infographic.
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？
